biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > S&P Biotech ETF enters bull market up 29% in 13 trading days

<< Previous

Bullboard Posts

Next >>

Comment by KayakerBCon Aug 08, 2022 11:42am

173 Views

Post# 34878843

RE:RE:RE:RE:S&P Biotech ETF enters bull market up 29% in 13 trading days

Money is flooding the sector.

A common fallacy. Other than IPOs and share offerings, money doesn't "flood" or flow into the stock market or any part of it. That's part of the fallacy of "cash on the sidelines". Money doesn't flow into or out of the stock market -- it flows through it. Any stock that is purchased is sold by someone else, at the same price. Stocks move up because buyers are more enthusiastic than sellers -- again, not because of an increased "flow" of money into the market.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments